Home Newsfeeds VEON Q4 Sales $940.00M Down From $2.05B YoY

VEON Q4 Sales $940.00M Down From $2.05B YoY

VEON (NASDAQ:VEON) reported $940.00 million in sales this quarter. This is a 54.19 percent decrease over sales of $2.05 billion the same period last year.

byBenzinga Newsdesk

March 16, 2023

1 minute read

VEON (NASDAQ:VEON) reported $940.00 million in sales this quarter. This is a 54.19 percent decrease over sales of $2.05 billion the same period last year.

Gold Jumps Over 2%; Wells Fargo Earnings Top Views

By Avi Kapoor

April 12, 12:06 PM

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Friday. The Dow traded down 0.82% to 38,143.73 while the NASDAQ fell 1.16% to 16,252.28. The S&P 500 also fell, dropping, 0.98% to 5,147.87.

APLD

Credit Suisse Initiates Coverage On Best Buy Co with Neutral Rating, Announces Price Target of $90

By Benzinga Newsdesk

December 20, 7:44 AM

Credit Suisse analyst Karen Short initiates coverage on Best Buy Co (NYSE:BBY) with a Neutral rating and announces Price Target of $90.

BBY

News

AstraZeneca Announced Datopotamab Deruxtecan-based Combinations Show Promising Clinical Activity in Patients With Advanced Non-small Cell Lung Cancer

By Charles Gross

August 9, 6:08 AM

Initial results from the TROPION-Lung02 Phase Ib trial showed that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy demonstrated promising clinical activity and a tolerable safety profile in patients with previously untreated or pretreated, advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations.

AZN